Abstract
Abstract Patent pledge financing in China's biomedical industry is in its infancy. The established system is far from perfect, and there are many coexisting financing channels. Based on data from the Chinese patent publication database and the database of drug manufacturers, the authors conducted a comprehensive analysis of patent pledge financing using Chinese pharmaceutical companies as the sample and propose measures for the development of patent financing for the biopharmaceutical industry in China in view of the outstanding problems. In the future, the Chinese government needs to provide preferential policies and economic support to a patent value evaluation system, patent technology market trading platform, and diversified risk-sharing mechanism.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
